/ADCT

ADCT Stock - ADC Therapeutics S.A.

Q: What is the analyst price target for ADCT?

Analyst price target information is not currently available for ADCT.

Q: What is ADCT's market cap?

Market capitalization information is not currently available for ADCT.

Healthcare|Biotechnology|NYSE

$3.73-4.36%

$0.17 (-4.36%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

100

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+101.1%upside

Target: $7.50

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for ADCT

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta1.89

52W High$4.80

52W Low$1.05

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$70.84M	$69.56M	$209.91M	$33.92M	N/A
Gross Profit	$64.89M	$67.03M	$206.61M	$32.52M	$-141,816,000
Gross Margin	91.6%	96.4%	98.4%	95.9%	N/A
Operating Income	$-130,654,000	$-165,986,000	$-123,344,000	$-261,720,000	$-219,263,000
Net Income	$-157,846,000	$-240,053,000	$-157,128,000	$-230,026,000	$-246,290,000
Net Margin	-222.8%	-345.1%	-74.9%	-678.2%	N/A
EPS	$-1.62	$-2.94	$-1.99	$-3.00	$-3.77

Company Overview

ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL in second-line transplant-ineligible patients; and Phase I clinical trial for treatment of relapsed or refractory non-hodgkin lymphoma (NHL). The company is also developing camidanlumab tesirine, an ADC that has completed Phase I clinical trial to treat relapsed or refractory NHL; in Phase II clinical trial in relapsed or refractory hodgkin lymphoma; and in Phase Ib clinical trial for selected advanced solid tumors. In addition, it develops ADCT-602, which is in Phase Ia clinical trial for treatment of acute lymphoblastic leukemia; ADCT-601 and ADCT-901 that are in Phase Ia clinical trial for treatment of various solid tumors; and preclinical product candidates, including ADCT-701 and ADCT-901 for the treatment of solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

20%

Hold / Neutral

60%

Sell / Underperform

20%

Analyst Consensus🔴 Bearish

1 Bullish4 Neutral/Bearish

Price Targets

Average Target

↑ 106.8% Upside

Now

Low

Average

$12

High

Based on 7 analysts

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
November 8th 2024	Stephens	Initiation	Overweight	$6
May 30th 2024	Cantor Fitzgerald	Initiation	Overweight	-
March 28th 2024	Guggenheim	Initiation	Buy	$11
August 10th 2023	JP Morgan	Upgrade	Neutral	-
April 24th 2023	BofA Securities	Downgrade	Underperform	$2← $7
December 6th 2022	CapitalOne	Initiation	Overweight	$12
November 9th 2022	BofA Securities	Downgrade	Neutral	$7← $14
September 21st 2022	JP Morgan	Initiation	Overweight	$5
September 9th 2022	Morgan Stanley	Downgrade	Equal Weight	$11← $17

Earnings History & Surprises

ADCT

Beat Rate

68%

Last 19 quarters

Avg Surprise

+4.8%

EPS vs Estimate

Beats / Misses

13/5

1 met exactly

Latest EPS

$-0.30

Q4 2025

EPS Surprise History

Q1 24

-119.1%

$-1.03vs$-0.47

Q2 24

0.0%

$-0.56vs$-0.56

Q3 24

+13.6%

$-0.38vs$-0.44

Q4 24

-16.7%

$-0.42vs$-0.36

Q1 25

+17.1%

$-0.29vs$-0.35

Q2 25

+5.3%

$-0.36vs$-0.38

Q3 25

-38.9%

$-0.50vs$-0.36

Q4 25

+25.0%

$-0.30vs$-0.40

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q1 2026	Mar 26, 2026	$-0.32	—	—	—
Q4 2025	Nov 10, 2025	$-0.40	$-0.30	+25.0%	✓ BEAT
Q3 2025	Aug 12, 2025	$-0.36	$-0.50	-38.9%	✗ MISS
Q2 2025	May 14, 2025	$-0.38	$-0.36	+5.3%	✓ BEAT
Q1 2025	Mar 27, 2025	$-0.35	$-0.29	+17.1%	✓ BEAT
Q4 2024	Nov 7, 2024	$-0.36	$-0.42	-16.7%	✗ MISS
Q3 2024	Aug 6, 2024	$-0.44	$-0.38	+13.6%	✓ BEAT
Q2 2024	May 6, 2024	$-0.56	$-0.56	0.0%	= MET
Q1 2024	Mar 13, 2024	$-0.47	$-1.03	-119.1%	✗ MISS
Q4 2023	Nov 7, 2023	$-0.61	$-0.58	+4.9%	✓ BEAT
Q3 2023	Aug 8, 2023	$-0.44	$-0.58	-31.8%	✗ MISS
Q2 2023	May 9, 2023	$-0.80	$-0.74	+7.5%	✓ BEAT
Q1 2023	Feb 28, 2023	$-0.49	$-0.30	+38.8%	✓ BEAT
Q4 2022	Nov 8, 2022	$-0.51	$-0.65	-27.5%	✗ MISS
Q3 2022	Aug 9, 2022	$-0.96	$-0.73	+24.0%	✓ BEAT
Q2 2022	May 9, 2022	$-0.76	$-0.36	+52.6%	✓ BEAT
Q1 2022	Mar 3, 2022	$-0.87	$-0.39	+55.2%	✓ BEAT
Q4 2021	Nov 2, 2021	$-0.97	$-0.59	+39.2%	✓ BEAT
Q3 2021	Aug 3, 2021	$-0.84	$-0.70	+16.7%	✓ BEAT
Q2 2021	May 6, 2021	$-1.00	$-0.74	+26.0%	✓ BEAT